Ka-Liong Tan (Dr.)
BSc., MSc., DPhil.
Ka-Liong Tan (Dr.) received his DPhil. from the University of Oxford in England, working on the chaperones and function of its client protein with Francesco Pezzella (Prof.). He joined the Faculty of Medicine and Health Sciences (FPSK) at USIM since 2017.
Tan’s current research interests focus on the translational aspects in breast cancer. He studies how hypoxia regulates the cell cycle of cancer cells through NUB1 protein. Besides, he is also keen on developing chromatography methods capable of determining anti-cancer drug concentration in patients’ blood. The other interests include
- Anti-cancer drugs therapeutic drug monitoring
- Targeted therapy – Imatinib, Nilotinib
- Tumour Pathology
- Cell cycle regulation
- Prognostic and predictive markers
His collaborators include
- Professor Francesco Pezzella (University of Oxford, UK)
- Professor Oreste Acuto (University of Oxford, UK)
- Professor Ravindran Ankathil (Universiti Sains Malaysia, MY)
- Dr. Noraidatulakma Abdullah (Universiti Kebangangsaan Malaysia, MY)
- Dr. Shing Cheng Tan (Universiti Kebangsaan Malaysia, MY)
Tan is an ambassodor for European Association of Cancer Research. He is passionate about experimental works and always eager to connect with other researchers.
- Tan et al. (2011) Determination of Imatinib Mesylate (GleevecTM) and Its Active Metabolite (N-desmethyl imatinib or CGP 74588) in Serum Samples using Protein Precipitation Method Coupled with Ultra-High Performance Liquid Chromatography-UV Detection. J Chrom B
- 2. Tan et al. (2016) Inhibition of NEDD8- and FAT10-ligase activities through degrading enzyme NUB1 – A potential anticancer approach. Onc lett.